ResearcherAsahikawa Medical UniversityNo recent work listed
Koji Imai
Matched on ORCID iD 0000-0001-9318-1450; OpenAlex author ID A5063761414. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 20
2015: 1 paper · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: none · 2020: 1 paper
Papers 4
- Clinical Outcomes of Biliary Drainage during a Neoadjuvant Therapy for Pancreatic Cancer: Metal versus Plastic Stents. Co-author DOI 10.5009/gnl18573↗
- Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Results from a randomised phase III trial (… Co-author DOI 10.1016/j.ejca.2018.01.081↗
- Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Co-author DOI 10.1016/s0140-6736(16)30583-9↗
- Metachronous pancreatic cancer originating from disseminated founder pancreatic intraductal neoplasias (PanINs). Co-author DOI 10.1002/cjp2.8↗
Closest collaborators
The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Satoshi Hirano · 3 shared papers, 2016–2020 · strength 0.21
- Paper Clinical Outcomes of Biliary Drainage during a Neoadjuvant Therapy for Pancreatic Cancer: Metal versus Plastic Stents. DOI 10.5009/gnl18573↗
- Paper Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Res… DOI 10.1016/j.ejca.2018.01.081↗
- Paper Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-… DOI 10.1016/s0140-6736(16)30583-9↗
- Akira Fukutomi · 2 shared papers, 2016–2018 · strength 0.11
- Paper Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Res… DOI 10.1016/j.ejca.2018.01.081↗
- Paper Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-… DOI 10.1016/s0140-6736(16)30583-9↗
- Shoji Nakamori · 2 shared papers, 2016–2018 · strength 0.11
- Paper Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Res… DOI 10.1016/j.ejca.2018.01.081↗
- Paper Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-… DOI 10.1016/s0140-6736(16)30583-9↗
- Takeshi Sudo · 2 shared papers, 2016–2018 · strength 0.11
- Paper Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Res… DOI 10.1016/j.ejca.2018.01.081↗
- Paper Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-… DOI 10.1016/s0140-6736(16)30583-9↗
- Yuji Kaneoka · 2 shared papers, 2016–2018 · strength 0.11
- Paper Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Res… DOI 10.1016/j.ejca.2018.01.081↗
- Paper Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-… DOI 10.1016/s0140-6736(16)30583-9↗
- Narikazu Boku · 2 shared papers, 2016–2018 · strength 0.11
- Paper Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Res… DOI 10.1016/j.ejca.2018.01.081↗
- Paper Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-… DOI 10.1016/s0140-6736(16)30583-9↗
- Naohiro Sata · 2 shared papers, 2016–2018 · strength 0.11
- Paper Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Res… DOI 10.1016/j.ejca.2018.01.081↗
- Paper Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-… DOI 10.1016/s0140-6736(16)30583-9↗
- Katsuhiko Uesaka · 2 shared papers, 2016–2018 · strength 0.11
- Paper Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Res… DOI 10.1016/j.ejca.2018.01.081↗
- Paper Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-… DOI 10.1016/s0140-6736(16)30583-9↗
- Yasuo Ohashi · 2 shared papers, 2016–2018 · strength 0.11
- Paper Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Res… DOI 10.1016/j.ejca.2018.01.081↗
- Paper Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-… DOI 10.1016/s0140-6736(16)30583-9↗
- Yukiyasu Okamura · 2 shared papers, 2016–2018 · strength 0.11
- Paper Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Res… DOI 10.1016/j.ejca.2018.01.081↗
- Paper Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-… DOI 10.1016/s0140-6736(16)30583-9↗
- Ippei Matsumoto · 2 shared papers, 2016–2018 · strength 0.11
- Paper Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Res… DOI 10.1016/j.ejca.2018.01.081↗
- Paper Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-… DOI 10.1016/s0140-6736(16)30583-9↗
- Soichiro Morinaga · 2 shared papers, 2016–2018 · strength 0.11
- Paper Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Res… DOI 10.1016/j.ejca.2018.01.081↗
- Paper Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-… DOI 10.1016/s0140-6736(16)30583-9↗
- Tsuyoshi Hayashi · 1 shared paper, 2020 · strength 0.10
- Masaki Kuwatani · 1 shared paper, 2020 · strength 0.10
- Yasutoshi Kimura · 1 shared paper, 2020 · strength 0.10
- Toru Nakamura · 1 shared paper, 2020 · strength 0.10
- Masayo Motoya · 1 shared paper, 2020 · strength 0.10
- Yasuhiro Hagiwara · 1 shared paper, 2018 · strength 0.06
- Junpei Sasajima · 1 shared paper, 2015 · strength 0.04
- Yusuke Mizukami · 1 shared paper, 2015 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.